Skip to main content

Table 4 Association between M-, T- and C- scores and clinical outcome in STOP-IgAN patients (available cases analysis)

From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)

 

M0 events/ total

M1 events/ total

p-value

T0 events/ total

T1/2 events/ total

p-value

C0 events/ total

C1/2 events/ total

p-value

Full clinical remissiona

8/48 (17%)

0/17 (0%)

0.099

6/39 (15%)

2/26 (8%)

0.460

4/45 (9%)

4/20 (20%)

0.238

GFR-loss ≥15 ml/min

14/51 (27%)

9/18 (50%)

0.092

11/40 (28%)

12/29 (41%)

0.302

16/47 (34%)

7/22 (32%)

1.000

ESRDb

7/51 (14%)

1/18 (6%)

0.671

1/40 (3%)

7/29 (24%)

0.008

4/47 (9%)

4/22 (18%)

0.255

Disappearance of microhematuria

11/34 (32%)

3/15 (20%)

n.d. c

10/29 (35%)

4/20 (20%)

n.d. c

10/34 (29%)

4/15 (27%)

1.000

Absolute annual GFR change (ml/min/1.73m2)

−0.79 ± 4.50

−5.06 ± 5.17

0.002

−2.05 ± 5.40

−2.01 ± 4.54

0.362

− 2.66 ± 5.02

−0.82 ± 5.02

0.131

  1. aurinary protein-creatinine ratio < 0.2 g/g and an eGFR decrease of < 5 ml/min/1.73m2
  2. bend-stage renal disease
  3. cnot determined (due to the low total numbers of available data points in this category, n = 49)